BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Novy Z, Laznickova A, Mandikova J, Barta P, Laznicek M, Trejtnar F. The effect of chelator type on in vitro receptor binding and stability in 177 Lu-labeled cetuximab and panitumumab: In vitro binding of 177 Lu-labeled cetuximab and panitumumab. J Label Compd Radiopharm 2014;57:448-52. [DOI: 10.1002/jlcr.3204] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Pandey U, Gamre N, Lohar SP, Dash A. A systematic study on the utility of CHX-A''-DTPA-NCS and NOTA-NCS as bifunctional chelators for 177Lu radiopharmaceuticals. Appl Radiat Isot 2017;127:1-6. [PMID: 28478331 DOI: 10.1016/j.apradiso.2017.04.028] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
2 Pandey U, Gamre N, Kumar Y, Shetty P, Sarma HD, Dash A. A systematic evaluation of the potential of PCTA-NCS ligand as a bifunctional chelating agent for design of 177Lu radiopharmaceuticals. J Radioanal Nucl Chem 2016;307:187-94. [DOI: 10.1007/s10967-015-4281-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
3 Chakravarty R, Chakraborty S, Sarma HD, Nair KV, Rajeswari A, Dash A. (90) Y/(177) Lu-labelled Cetuximab immunoconjugates: radiochemistry optimization to clinical dose formulation. J Labelled Comp Radiopharm 2016;59:354-63. [PMID: 27264196 DOI: 10.1002/jlcr.3413] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
4 Kostelnik TI, Orvig C. Radioactive Main Group and Rare Earth Metals for Imaging and Therapy. Chem Rev 2019;119:902-56. [PMID: 30379537 DOI: 10.1021/acs.chemrev.8b00294] [Cited by in Crossref: 123] [Cited by in F6Publishing: 84] [Article Influence: 30.8] [Reference Citation Analysis]